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European Journal of Cardio-thoracic Surgery 32 (2007) 834—838AbstractBackground: We observed a remarkable increase in the number of young patients who presented with lung emphysema and secondary
spontaneous pneumothorax (SSP) at our institution for over a period of 30months; most of them have a common history ofmarijuana abuse. Study
design: Retrospective case series.Methods: Seventeen young patients presented with spontaneous pneumothorax with bullous lung emphysema
were systematically evaluated over a period of 30 months. All were regular marijuana smokers. Clinical history, chest X-ray, CT-scan, lung
function test, and laboratory and histological examinations were assessed. We compared the findings of this group (group I) with the findings of
non-marijuana smoking patients (group II) in the same period. The findings of this series were also compared with the findings of 75 patients
presented with pneumothorax in a previous period from January 2000 till March 2002 (group III). Results: In group I, there were 17 patients: the
median age of the patients was 27 years (range 19—43 years), 16 males and 1 female. All were living in Switzerland. All but one smokedmarijuana
daily for a mean of 8.8 years and tobacco for 11.8 years. CT-scan showed multiple bullae at the apex or significant bullous emphysema with
predominance in the upper lobes only in two patients. Only two patients had reduced forced first second expiratory volume (FEV1) and one
reduced vital capacity (VC) below the predicted 50%. This correlated with the subjectively asymptomatic condition of the patients. All but two
patients were treated by video-assisted thoracoscopic surgery (VATS) for prevention of relapsing pneumothorax. Histology showed severe lung
emphysema, inflammation, and heavily pigmentedmacrophages. In group II, there were 85 patients: there were 78males, the median age was 24
years (range 17—40 years), 74 patients smoked tobacco for 13.4 years but no marijuana. CT-scan in 72 patients showed only small bullae at the
apex but no significant emphysema; other clinical, laboratory, and histopathological findings showed no significant difference in group I. In group
III, there were 75 patients: there were 71males and 4 females. Mean agewas 25 years (range 16—46 years). Six smokedmarijuana daily for amean
of 3.2 years, and 62 smoked tobacco for 14 years. CT-scan done in 59 patients showed few small bullae at the apex but no significant lung
emphysema. The presence of lung emphysema on CT-scan in group I was significantly different than in groups II and III ( p = 0.14). No significant
difference was found among all groups in the form of clinical, laboratory, and histopathological findings. Conclusions: In case of emphysema in
young individuals, marijuana abuse has to be considered in the differential diagnosis. The period ofmarijuana smoking seems to play an important
role in the development of lung emphysema. This obviously quite frequent condition in young and so far asymptomatic patients will havemedical,
financial, and ethical impact, as some of these patients may be severely handicapped or even become lung transplant candidates in the future.
# 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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A surprising increase in the number of young adults with
secondary pneumothorax due to lung emphysema was
observed. These so far oligosymptomatic patients presentedAbbreviations: SSP, secondary spontaneous pneumothorax; FEV1, first
second forced expiratory volume; VC, vital capacity; VATS, video-assisted
thoracic surgery; CRP, C-reactive proteins.
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doi:10.1016/j.ejcts.2007.07.039at the surgical emergency unit, as the condition manifested
first with a pneumothorax.
Marijuana smoking peaked in 1979 and decreased
continuously thereafter until the early 1990s. Since then,
according to a recently published national survey on
substance abuse in the United States, prevalence of
marijuana smoking has increased continuously in high school
and college students, as well as in young adults aged 19—32
years. In 1999 prevalence (use within the past month) was
23% in high school seniors, 19% in college students, and 15% in
young adults. Daily use was reported by 6.0% of high school
students, 4.0% of college students, and 4.4% of young adults
[1]. Similarly, the number of the 14—15-year-olds who tried
cannabis rose from 19% to 29% in boys and 18% to 25% in girls inurgery. Published by Elsevier B.V. All rights reserved.
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with the ones in countries like The Netherlands or Switzer-
land, which have a more liberal drug policy. In a large survey
on health in Switzerland in 2002, 19.5% of the population
between 15 and 64 years had experience with cannabis
products of which 18% were between 15 and 34 years old.
4.6% declared consumption on a regular basis and one-half of
them at least once a week. The overall consumption in the
Swiss population increased from 16.3% of the 15—39-year-
olds in 1992 to 27.7% in 2002 [3]. The annual production of
cannabis in Switzerland is thought to be 200 tons. In the
editorial in the British Journal of Medicine by Henry et al. the
number of cannabis smokers in the UK was estimated to be
3.2 millions [2]. The impact of cannabis on the health of the
general population is most probably underestimated.2. Patients and methods
2.1. Study design
Among the 102 patients who presented with spontaneous
pneumothorax at the emergency unit of our institution within
a 2.5-year period (April 2002—October 2004), 17 patients who
had relevant pulmonary emphysema and history of marijuana
and nicotine abuse were retrospectively systematically
evaluated. Two female patients who met the criteria of
the study were excluded as no surgical treatment was
needed. Retrospectively, we compared the findings of this
group with the findings of non-marijuana smoker pneu-
mothorax patients in the same period. The findings of this
series were also compared with the findings of all
pneumothorax patients who were operated upon in a
previous period from January 2000 until March 2002. The
patients were divided into three groups: group I, 17 patients
(marijuana smoking patients, April 2002—October 2004);
group II, 85 patients (non-marijuana smoking patients in the
same period); and group III, 75 patients (all pneumothorax
patients operated on from January 2000 to March 2002). Age,
sex, nicotine abuse, laboratory, radiological findings, histo-
pathological findings, operative procedures, and outcome
were compared. p-value was significant under 0.05%.
2.2. Diagnosis and management
After admission, all patients underwent clinical examina-
tion and standard laboratory examinations. Not all examina-
tions could be performed on all patients due to suboptimal
compliance. A chest X-ray was performed and a 24F chest
drain was inserted under local anesthesia. Serum a1-
antitrypsin levels were measured in 16 patients in group I,
5 patients in group II, and 7 patients in group III. CT-scan of
the chest could be performed in 15 patients in group I, 74
patients in group II, and 59 patients in group III. Lung function
was done in 12 patients in group I, 70 patients in group II, and
62 patients in group III.
2.3. Surgical treatment
In group I, surgical treatment for the prevention of
recurrent pneumothorax by VATS was done in 15 patients.Two refused surgery and were treated with chest tube
insertion only. In group II, VATS was done in 65 patients (5
patients had the first episode, 58 patients had the second
episode, and 2 patients had recurrence after previous VATS).
In group III, VATS was done in 50 patients (3 patients had
pneumothorax for the first time, 46 patients had the second
episode, and 1 patient had recurrence after previous VATS).
In all groups, the surgical procedures using VATS for
bullectomy and/or resection of the apex (Endo GIA 45,
Ethicon Endosurgery, Cincinnati OH) in addition to pleural
abrasion were performed. For bullectomy done mostly in
group I, 4—6 cartridges have been used. In case of apex
resection 1—3 cartridges were needed. Pleura abrasion over
the upper five ribs was done in all first or second episode of
pneumothorax. In case of recurrence after VATS, pleurect-
omy was performed.3. Results
3.1. Medical history
The main complaints at the time of admission were
shortness of breath (n = 12 in group I, n = 68 in group II, and
n = 61 in group III), pleuritic chest pain (n = 5 in group I, n = 12
in group II, and n = 9 in group III), and/or cough (n = 9 in group
I, n = 18 in group II, and n = 14 in group III). Onset of these
symptoms varied between a few hours and several days
before admission.
In group I, all but one patient had an uneventful medical
history. This patient had been previously diagnosed with
emphysema on a routine chest X-ray by his family doctor, but
no treatment was necessary. No patient was on any regular
medication. The median BMI was 19.2 kg/m2 (range 16.5—
28 kg/m2).
Marijuana consumption on a daily basis was noted in 16
patients (median 6 joints/day), 1 patient smoked marijuana
only three times per week and did not smoke cigarettes. All
other patients had additional nicotine abuse (mean 7 pack
years, range 3—25 pack years). The mean duration of
marijuana smoking was 8.8 years (range 3—20 years). In all
patients it was shorter than the duration of tobacco smoking
(11.6 years, range 4—23 years). Four patients reported a
sporadic cocaine use, one LSD over 3 years, and one had
sporadic heroin abuse. In group II, 3 patients had known
allergic reaction, 1 patient had bronchial asthma, and 74
patients smoked tobacco for 13.4 years. In group III, no
medical history was known; 6 smoked marijuana daily for a
mean of 3.2 years, and 62 smoked tobacco for 14 years.
3.2. Physical examination
Physical examination and review of systems did not reveal
any particular findings except the typical signs of pneu-
mothorax and/or emphysema with no significant difference
in all groups.
3.3. Laboratory findings
Routine laboratory did not show any pathological findings,
except in one patient who had elevated leucocytes and CRP
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Fig. 2. (A, B) Chest CT-scan showing bilateral peripheral bullous emphysema.
The pleural drain is in situ on the left side.values due to an infected bulla. The measurements of a1-
antitrypsin serum levels were in the normal range with a
median of 1.5 g/l (normal values 0.83—1.99 g/l). One patient
had a borderline value in group I, two patients in group II, and
one patient in group III.
3.4. Lung function
The overall pulmonary function of the 12 patients who
agreed to undergo lung function testing was normal with a
median FEV1 of 4.5 l (mean 3.8 l, range 2.2—5.0 l) and a
median FVC of 5.7 l (mean 4.9 l, range 3.9—6.5 l). Only two of
these patients had reduced FEV1 of the predicted 31% and
33% (1.2 and 1.7 l) and only one of them had FVC of 2.5 l
(59%). In all other patients the values were above the
predicted 89%. The overall pulmonary function performed in
70 patients in group II and in 62 patients in group III showed no
significant difference to group I ( p = 0.062).
3.5. Radiological findings
Chest X-ray was done in all patients; CT-scan performed in
88% (n = 15) in group I, in 85% (n = 72) in group II, and in 79%
(n = 59) in group III has been examined by our radiologist.
Similar findings with different severity of peripheral
emphysema and apical bullae were noted in all patients in
group I (Fig. 1A and B, Fig. 2A and B). The distribution of the
emphysema was homogenous in two patients with predomi-
nance in the upper fields. The bullae varied in size from
0.3 cm to 12 cm. In one patient a fluid level in a bulla was
noted, indicating infection. In three patients the upper lobes
were almost completely replaced by large bullae. On the
other hand, there was no lung emphysema reported in the
other two groups ( p = 0.014), apart from very small bullae
1 cm in diameter at the apex of the lung in 84% in group II
and 89% in group III. These small bullae were more on the
right side ( p = 0.12).
3.6. Histopathological examination
The histopathological examination showed the presence
of bullae with destruction of the acinar wall and the
respiratory bronchioles with focal alveolar edema. In
addition, the alveolar and bronchiolar lumina were focallyFig. 1. (A, B) Chest X-ray showing signs of emphysema (32-year-old male).
Pleural drain is on the right side.filled with heavily pigmented macrophages. The alveolar
septa were markedly thickened by a fibrotic stroma. The
same pigment as in the macrophages could be found in the
fibrotic stroma and the thickened pleura. A moderate
inflammatory infiltrate and fibrinous exudate was present
(Fig. 2A and B). In all other patients there was no significant
difference in the histological findings apart from the obvious
smaller bullae at the apex of the lung (Fig. 3).
3.7. Recurrence after VATS
The overall recurrence rate after VATS was 3% and there
was no significant difference in all groups.4. Discussion
Over a period of 30 months we observed a remarkable
increase in secondary spontaneous pneumothorax in other-
wise healthy young adults. All patients were in good general
condition, which was in contrast to the radiological findings.
The risk of developing pneumothorax after tobacco
smoking or alkaloid cocaine consumption is described
[4,5]. A few reports of pneumothorax or pneumomediastinum
following combined use of marijuana, heroine, or cocaine
have been published [6—9]. Recently, a bilateral spontaneous
pneumothorax was, however, reported in a 23-year-old
cannabis smoker with normal lung parenchyma in the CT-scan
[10]. But these reports describe single and supposedly rare
cases.
Cannabis has been used over five millennia for the
treatment of many conditions including pain, inflammation,
neuralgia, migraine, and dysmenorrhea. It has also been used
as an anticonvulsant, muscle relaxant, and for restlessnessFig. 3. (A) Histological sample of an apical pulmonary resection showing
subpleural bullae, the focal alveolar edema (arrow), and the focal consolida-
tion (arrowhead) (hemalaun and eosin, bar 1000 mm). (B) Subpleural inter-
stitial fibrotic area. Note the heavily pigmented alveolar macrophages
(arrowhead), the same pigment deposited in the fibrotic stroma (arrow)
and the thickened pleura with amoderate inflammatory infiltrate and fibrinous
exudation (hemalaun and eosin, bar 100 mm).
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Table 1
Summary of history and findings of group I with secondary spontaneous
pneumothorax and lung emphysema
Median 25th/75th
percentile
Age 27 23.3/31.8
BMI 19.2 18.4/20
Smoking history
Marijuana (joints/day) 6 3/10
Duration (years) 7 5.3/11.8
Tobacco (packs/day  years) 7 3/10
Duration (years) 12.5 9/15.8
Lab
Alpha1-antitrypsin (g/l) (NR 1.1—2.1) 1.5 1.3/1.6
Lung function tests
FVC (l) (% predicted) 5.5 (98) 4.2/5.7
FEV1 (l) (% predicted) 4.2 (90) 2.7/4.5
FEV1/FVC (%) 77.8 70/82and anxiety in terminal illness [11,12]. In the early 1970s itwas
deemed to be of littlemedical use andwas removed frommost
medication lists. Thereafter, studies have demonstrated a
bronchodilator response as aphysiological short-termeffect of
inhaled marijuana. This may be attributed to the pharmaco-
logic effect of g9-tetrahydrocannabinol [13,14] and the
stimulation of the cannabinoid-1 receptor on postganglionic
parasympathetic nerve endings on airway smooth muscle,
leading to inhibitionofacetylcholine release [15]. Someknown
consequences of habitual marijuana smoking include an
increased prevalence of chronic cough, sputum production,
and wheeze, as well as a higher frequency of acute bronchitis
[16—18]. In addition, the risk for myocardial infarction seems
to be increased by 4.2 times within an hour after smoking
cannabis [2] and the risk for psychosis is increased especially in
young adults with a predisposition [19].
Interestingly enough the CT-scan performed in 72 patients
in group II and in 59 patients in group III showed only small
bullae (under 1 cm in diameter) at the apex with no signs of
emphysema of the lung, even in patients who smoked
marijuana over a period of 3 years in group III. We oppose that
the period of marijuana smoking is an important factor in the
development of lung emphysema in these patients. There
was no significant difference in the length of the thoracic
drainage or in the length of hospital stay between all groups.
The rate of recurrence after VATS was not significantly higher
in patients with secondary pneumothorax who smoked
marijuana.
In a small case series of four patients, three of them from
West India with significant exposure to marijuana, the authors
describe multiple bullae in the upper lung fields and little
parenchymal lung disease elsewhere. As three of these
patients had limited tobacco use, those authors concluded
that marijuana smoking is the reason for the parenchymal
changes, possibly accelerated by tobacco smoking [20]. In
contrast,weobserveda significant lung change inpatientswho
smokedmarijuana for a longer period than 3 years, as well as a
homogeneous distribution of emphysema in this series,
unlikely to be tobacco emphysema, the so far largest single-
center series fromawestern country, but a predominant upper
lobe emphysema was noticed in two patients, which may
confirm the findings by other authors as well.
In western countries, the condition seems to be much
more frequent. Based on our observations and the prevalence
of cannabis smoking in developed countries, we propose to
introduce the term ‘joint years’ (joints/day times years of
abuse) to assess the severity of the exposure, as it seems that
one joint per day is equivalent to at least to one packet of
cigarettes per day.
Subjectively, these young patients were asymptomatic
and most of them still had normal lung volumes. Therefore,
they only consulted a doctor when the pneumothorax
occurred.
The increase of young patients with emphysema,
associated with an increase in cannabis smoking in young
adults in many countries, may create major health problems
in future with a strongmedical, financial, and ethical impact,
as a number of these patients may be severely handicapped
or even end up as lung transplant candidates. The public
awareness of the health hazards by cannabis smoking has to
be increased (Table 1).References
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